Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative

Abstract

A medicine which comprises a combination of an acetylcholine esterase inhibitor and a 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative represented by the following general formula (I). It is useful for the treatment of memory disorders accompanying neuropsychiatric diseases and other cognition disorders. Also provided are: a method of treatment of any of these diseases which comprises using a combination of these drugs; and a use of the medicine. (In the formula (I), Het is oxadiazolyl; R<1> is hydrogen, lower alkyl, cyclo(lower alkyl), lower alkenyl, lower alkoxy, (un)substituted aryl, (un)substituted heteroaryl, etc.; and R<2> is hydrogen, lower alkyl, cyclo(lower alkyl), (un)substituted aryl, etc.).

Description

technical field [0001] The present invention relates to a medicament comprising an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative or a physiologically acceptable acid addition thereof A combination of salts; a method of treating memory impairment (memory dysfunction) and other cognitive impairment associated with neuropsychiatric diseases, the method comprising administering the medicament; and uses thereof. Background technique [0002] As society ages, the increase in Alzheimer's patients has caused social problems. About 90% of senile dementia patients are vascular dementia caused by Alzheimer's dementia and cerebrovascular disease. As for the symptoms of dementia, impairment of short-term or long-term memory is the basic and common core symptom observed. In dementia patients, the function of various neurotransmitter systems, mainly in the cerebral cortex and limbic system, is significantly reduced, as is the funct...

AI Technical Summary

Problems solved by technology

However, BZP receptor agonists are known to cause memory impairment (forgetting) as a side effect

Images